Close
Back to DYAX Stock Lookup

Dyax Corp (DYAX) – Company Press Releases

Jan 22, 2016 09:16 AM Shire Completes Acquisition of Dyax
Dec 11, 2015 08:00 AM Dyax Corp. Sets January 21, 2016 As Date of Special Stockholder Meeting To Vote On Its Proposed Acquisition By Shire plc
Dec 6, 2015 09:00 AM Dyax Corp. Presents DX-4012 Data at the 2015 American Society of Hematology Annual Meeting
Dec 2, 2015 05:26 PM Dyax Corp. Announces Early Termination of Hart-Scott-Rodino Waiting Period
Nov 17, 2015 08:00 AM Dyax Corp. Recognized as a “Top Place to Work” by The Boston Globe for Second Year in a Row
Nov 9, 2015 03:00 PM Dyax Corp. Presents Phase 1b DX-2930 Data at the American College of Allergy, Asthma, and Immunology Annual Meeting
Nov 4, 2015 09:11 AM Law Offices of Marc S. Henzel Announces Investigations of Globus Medical, Inc., USA Technologies, Inc., Constant Contact, Inc., Dyax Corp, Hutchinson Technology and MedAssets, Inc.
Nov 2, 2015 06:11 AM Dyax Corp. Announces Cancellation of Research and Development Day
Nov 2, 2015 06:00 AM Shire to Acquire Dyax Corp, Expanding and Extending Industry-Leading Hereditary Angioedema (HAE) Portfolio
Oct 28, 2015 04:01 PM Dyax Corp. Announces Third Quarter 2015 Financial Results
Oct 27, 2015 08:30 AM Dyax Corp. to Review Third Quarter 2015 Financial Results at Research and Development Day
Oct 26, 2015 04:30 PM Dyax Corp. to Webcast 2015 Research and Development Day
Oct 14, 2015 08:00 AM Dyax Corp. to Host Third Quarter 2015 Financial Results Call and Webcast
Sep 30, 2015 07:12 AM Dyax Corp. Receives Positive Opinion for Orphan Medicinal Product Designation in the European Union for DX-2930 for the Treatment of Hereditary Angioedema
Sep 22, 2015 08:00 AM Dyax Corp. to Participate in the Leerink Partners 4th Annual Rare Disease Roundtable
Sep 2, 2015 08:00 AM Dyax Corp. to Participate in the Morgan Stanley Global Healthcare Conference
Aug 12, 2015 07:00 AM Dyax Corp. Provides Update on DX-2930 Clinical and Commercial Supply Initiatives
Aug 6, 2015 07:12 AM Dyax Corp. to Participate in the 2015 Wedbush PacGrow Healthcare Conference
Jul 29, 2015 04:01 PM Dyax Corp. Announces Second Quarter 2015 Financial Results
Jul 15, 2015 08:00 AM Dyax Corp. to Host Second Quarter 2015 Earnings Call and Webcast
Jul 7, 2015 07:15 AM Dyax Corp. Receives FDA Breakthrough Therapy Designation for DX-2930 for Prevention of Attacks of Hereditary Angioedema
Jun 8, 2015 07:12 AM Dyax Corp. Presents Phase 1b DX-2930 Data at the 2015 European Academy of Allergy and Clinical Immunology Annual Congress
May 27, 2015 08:00 AM Dyax Corp. to Participate in the Jefferies 2015 Global Healthcare Conference
May 15, 2015 08:30 AM Dyax and the U.S. Hereditary Angioedema Association (HAEA) Launch the HAE Hope® Essay Contest on the Fourth Annual Hereditary Angioedema Day
May 12, 2015 04:30 PM Dyax Corp. Appoints Dr. Abbie Celniker to Board of Directors
Apr 30, 2015 05:14 PM Dyax Corp. to Participate in Upcoming Investor Conferences
Apr 29, 2015 04:01 PM Dyax Corp. Announces First Quarter 2015 Financial Results
Apr 16, 2015 08:00 AM Dyax Corp. to Host First Quarter 2015 Earnings Call and Webcast
Apr 13, 2015 02:12 PM Dyax Closes $230 Million Public Offering of Common Stock
Apr 9, 2015 08:00 AM Dyax Corp. to Participate in the 14th Annual Needham Healthcare Conference
Apr 7, 2015 08:47 PM Dyax Announces Pricing of $200 Million Public Offering of Common Stock
Apr 6, 2015 04:01 PM Dyax Announces Proposed Public Offering of 7,000,000 Shares of Common Stock
Mar 31, 2015 04:01 PM Dyax Announces Positive Results from Phase 1b Clinical Trial of DX-2930

Back to DYAX Stock Lookup